A multicenter, open-label, phase IIIb trial of Tarceva (erlotinib hydrochloride) in patients with advanced non-small cell lung cancer.
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2014
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Genentech
- 31 Oct 2006 Status change
- 17 Sep 2005 New trial record.